This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Artiva Biotherapeutics’s 8K filing here.
Artiva Biotherapeutics Company Profile
Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.
Further Reading
- Five stocks we like better than Artiva Biotherapeutics
- Election Stocks: How Elections Affect the Stock Market
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Why Are Stock Sectors Important to Successful Investing?
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- How to Calculate Stock Profit
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
